RE:RE:RE:RE:Re: Interesting quoteCiao, "We have no idea why the interested parties, advanced discussions, and serious discussions could not lead to a commerical PGX licensing deal. But I bet there are many failures there."
This merger with AEZS is materially a PGX deal. Based on H.C. Wainwrights target prices for AEZS over the last year, and that it is a merger of equals, it arguably values CZO's at a target price between C$1.25-C$2.20 per CZO share. That would obviously take PGX into account. Obviously deals AEZS has under discussion for its diagnostic and that CZO has talked about concerning PGX would be taken into account. Gilles is an insider of both companies and so is very well placed.
Carolyn Egbert, Chair of Aeterna: “Ceapro has well-established and growing commercial operations, with potential value-creating pipeline opportunities in large and growing cosmetic and consumer health markets. We believe that the new company will have the capital resources to support this ongoing growth..."
AEZS's Chair is obviously talking about PGX opportunities.